Business context and reporting period
Propanc Health Group Corporation is an early-stage biotechnology company developing pro-enzyme cancer treatments, primarily for pancreatic and colorectal cancers. Its lead program remained preclinical; the company had no products on the market and generated no revenue. This unaudited Form 10-Q covers the three months ended September 30, 2015, compared with the three months ended September 30, 2014. The filing describes this as the quarter ended September 30; the supplied request labels it 2015 Q1.
Financial results and liquidity
| Metric | Three months ended Sep. 30, 2015 | Three months ended Sep. 30, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1,007,391 | $238,138 |
| Operating loss | $(1,007,391) | $(238,138) |
| Net loss | $(838,894) | $(783,300) |
| Net loss per share | $(0.00) | $(0.01) |
| Cash used in operations | $(627,235) | $(99,810) |
Revenue and profit margins are not meaningful because the company had no sales and incurred losses. Net loss was partly offset by a $795,853 noncash gain from changes in derivative fair value; foreign currency transaction losses were $210,739. Other comprehensive income included a $258,430 foreign currency translation gain, leaving total comprehensive loss of $580,464.
At September 30, 2015, cash was $77,458, current assets were $299,914, total assets were $305,121, and current liabilities were $3,487,465. Working capital was negative $3,187,551; stockholders’ deficit was $3,182,344, and accumulated deficit was $21,804,565. Convertible notes and related accrued interest, net, were $2,148,900. The filing reports no conventional long-term debt balance; most liabilities were current.
Financing activities provided $415,338, including $552,500 in convertible-note proceeds, offset by note and loan repayments. Cash declined by $30,169 during the quarter. The company issued 9.18 million common shares during the quarter, increasing shares outstanding from 347.44 million at June 30 to 356.62 million at September 30; 397.08 million shares were outstanding November 13.
Material changes versus the prior comparable period
- Operating expenses rose by approximately $769,000. Administration expense increased to $848,979 from $231,482, driven mainly by higher stock-based compensation, wages and benefits, and professional fees.
- Research and development spending increased to $153,474 from $3,879, primarily for animal efficacy work, drug-substance and product manufacturing, and preclinical and toxicology activities.
- Interest expense declined to $418,644 from $548,479, while the derivative fair-value gain increased to $795,853 from $114,536.
- Net loss increased by $55,594, while operating cash use increased to $627,235 from $99,810.
Outlook, risks, contingencies and unusual items
- Going concern: The filing states that losses, operating cash use, and the working-capital and stockholders’ deficits raise substantial doubt about the company’s ability to continue as a going concern. Continued development depends on obtaining financing, advancing the program, patent protection, and ultimately achieving sufficient sales; there is no assurance these will occur.
- Subsequent financing: On October 1, the company received $1.15 million net of fees under a $1.2 million note. On October 28, it entered a $4 million investment transaction for a $4.4 million convertible debenture and warrants for 26,190,476 shares at $0.60 per share. The $1.2 million prior note was cancelled and included in the transaction. Of the investment amount, $2.8 million was placed in a controlled account pending milestones and equity conditions, so the full amount was not described as immediately available. The debenture carries 5% interest, has a 10% original issue discount, is secured by company assets under specified terms, and includes conversion-price adjustment provisions and default remedies. Management said the financing should provide funds for obligations over the next 12 months, but access to escrowed funds and other conditions remain material.
- Debt and dilution: Several outstanding convertible notes have variable-price or discounted conversion features, including conversion prices tied to recent low trading prices. Note conversions during and after the quarter issued substantial shares. The subsequent debenture also includes conversion rights and potential dilution; its warrants are separate potential dilution.
- Litigation: JMJ Financial claimed $25,000 under a convertible note. The company was defending the case, had filed a counterclaim, and was negotiating a possible settlement; mediation was expected in December 2015. Management did not expect a material adverse effect.
- Controls: Management concluded disclosure controls were ineffective because the small staff did not provide sufficient segregation of duties. The company planned to address this by hiring accounting personnel when resources permitted.
- Other risks: The company’s Australian bank deposits were uninsured. Its lead product remained preclinical, patent protection was incomplete across many targeted jurisdictions, and derivative fair values relied on Level 3 assumptions and a thinly traded stock. Loans from directors and an officer were past due and in default, although non-interest-bearing.
Important facts for investors to verify
- How much of the October financing is actually available for operations, and what milestones or equity conditions govern release of the $2.8 million controlled-account balance?
- Current cash, working capital, cash runway, and funding needs, given the going-concern warning and management’s 12-month financing expectation.
- Outstanding convertible-note principal, accrued amounts, conversion terms, defaults, and potential share issuance, including conversions after September 30.
- Progress toward preclinical milestones, clinical development, manufacturing, and patent grants; the filing does not provide a clear timeline for regulatory approval or commercialization.
- Status and financial exposure of the JMJ litigation, and remediation of the disclosed segregation-of-duties weakness.